truthtracer

Husband & Father. ✞ Proud USAF Vet, Biotech Investor. Spouse ~Molecular Cell Biologist/Regulatory Manager. #RNAi Observer w/corresponding opinions. DYODD

[truthtracer @truthtracer]

$ARWR It’s the inarguable news that matters. Not rumors, short sellers or naysayers. This company is beginning to mature. Fact remains that many do not have the mental facilities/acuity to simply stay the course when panic becomes wretchedly contagious.

[truthtracer @truthtracer]

@Chase_Senior @k49092 A lot of replies lean towards disbelief but with Burrow and a revitalized roster… ~Stranger things have occurred.

[truthtracer @truthtracer]

@Mxa77tetha @LindseyGrahamSC Hardly humiliating us. That’s an uninformed overreaction. It’s a process and the only negotiating tactics they seemingly understand thus far are violence and military superiority. Trump is giving them ample opportunity to choose between certain destruction or capitulation.

[truthtracer @truthtracer]

$ARWR On the leading edge of restorative medicine. A trillion dollar movement… https://t.co/4Uis6nyKU3

[ArrowheadPharma @ArrowheadPharma]

Our CEO, Chris Anzalone, Ph.D., recently sat down with @LABJnews to discuss recent milestones—including our first-ever FDA approval last month— and the #RNAi platform behind our growing pipeline.

Read the full article: https://t.co/3wcBjEdmuE

[truthtracer @truthtracer]

@KirkHerbstreit @Joey_Galloway It’s no mistake and no apology is necessary.

[truthtracer @truthtracer]

✔️Important point & predicts the path $ARWR is following. Both CEO Chris Anzalone and VP/Investor Relations Vince Anzalone have stated, it’s a “Shots on goal” business. The FDA notices this success ratio, as well. ~It bodes well for the future of both $ALNY & $ARWR

[truthtracer @truthtracer]

@MarketTrendAdv That RNAI sentiment has been echoed for 10+ years. The wild card was early expectations. Buying $ARWR now remains a very strong bet. $ALNY is a very apt growth comparison re RNA Interference future projections . ~POC creates a radically different 🐂 market dynamic for Arrowhead.

[truthtracer @truthtracer]

@MookTrader $ARWR U were heard…

[truthtracer @truthtracer]

@MookTrader $ARWR May/could be (❓) conservative if harkening back to the intoxicating adrenaline buzz days when $ARWR was frolicking in the $90’s ~on a wing and a prayer. ~Pre-drug approval & now concrete platform validation.

[truthtracer @truthtracer]

@BikeRieder $ARWR Give the Jeffries webcast a listen to have a better understanding of the likely (imo) impact that REDEMPLO®️will have on the elevated triglyceride patient population.

https://t.co/yrNdDGGHhW

[truthtracer @truthtracer]

@BikeRieder $ARWR Heathy volume of shares trading hands. Indicates institutional buyers clocking in (post comprehension) how broad utilization REDEMPLO® (plozasiran) (FDA’s) approval will impact the market for high triglycerides, i.e. ultimately a diverse grouping of applications.

[BikeRieder🇨🇭 @BikeRieder]

$ARWR
Another $200 million to receive within 60 days. Good news just continue to keep going.

[Robert Kruse, MD, PhD @RobertLKruse]

I’ve had the pleasure to work with Arrowhead to get expanded access to Plozasiran. It’s been life changing for my patient, like a miracle drug. Maybe the most humbling experience I’ve had in medicine to see a drug quickly cure a previously intractable disease. Congratulations!

[truthtracer @truthtracer]

@BikeRieder It’s just another way of saying you have endurance.😉

[truthtracer @truthtracer]

@BiomedicalRX With that $ARWR thought in mind; this could very well be the correct time to increase your position…

[truthtracer @truthtracer]

@AAGDhillon @TheJusticeDept You’re standing on a hill all by yourself, Gavin. California voters seek transparency first. You certainly shouldn’t fear election monitoring, you should embrace it. ~May the best man or woman (fairly) win…

[truthtracer @truthtracer]

$ARWR

[truthtracer @truthtracer]

Bonafide “STREET” cred is closely linked to FDA drug approval. Platform proof of concept will be greatly strengthened w/1st approved drug. Exceptional (recent) BP collaborations showcase demonstrable fundamental belief in $ARWR. ~Go big or go home, it’s always a personal choice…

[truthtracer @truthtracer]

$ARWR It’s the inarguable news that matters. Not rumors, short sellers or naysayers. This company is beginning to mature. Fact remains that many do not have the mental facilities/acuity to simply stay the course when panic becomes wretchedly contagious.

[truthtracer @truthtracer]

@thorku Cornerbacks and safeties must sometimes think the next time MaHomes pulls that chicken💩 he’s gotta get clocked. A little 70’s NFL retribution? It’s wearing thin, you can’t have it both ways and expect grown arse men to just stand idly by. ~Used to be the league of FAFO.

[truthtracer @truthtracer]

@TadMakowiecki Haven’t sold a share since my early investigations in 2013. ~Haven’t even been tempted. I’m an avid reader and remain an $ARWR Bull. I firmly believe that the long term Bull narrative is becoming increasingly easy to understand.

100% Tad, Tech & financing are locked & loaded…